Interní Med. 2008; 10(2): 58-61

What is the situation in the treatment of patients with hypertension and metabolic syndrome?

doc. MUDr. Miroslav Souček CSc
II. interní klinika FN u sv. Anny LF MU, Brno

Combination of clinical and metabolic factors that constitute metabolic syndrome has been explored thoroughly because of its high and constantly increasing prevalence in general population and clear relation of the syndrome to increased prevalence of cardiovascular diseases. The most important intervention is a life style change (dietary and physical activity modification), however in a number of patients further intervention including pharmacotherapy is indicated to influence blood pressure, obesity, lipids and blood sugar. The basic treatment of hypertension includes the blockade of renin-angiotensin system (ACE-inhibitors, sartans), that are frequently combined with other antihypertensive medications preferably metabolically neutral.

Keywords: metabolic syndrome, cardiovascular risk, renin-angiotensin system, ACE-inhibitors, sartans, metabolically neutral antihypertensives

Published: May 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Souček M. What is the situation in the treatment of patients with hypertension and metabolic syndrome? Interní Med. 2008;10(2):58-61.
Download citation

References

  1. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-risk of fatal cardiovascular disease in Europe: the SCORE Project. Eur Heart J 2003; 11: 987-1003. Go to original source... Go to PubMed...
  2. Cífková R, Horký K, Widimský J sr., et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2004. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2004; 50: 709-722. Go to PubMed...
  3. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOPHypertension). Lancet 1991; 338: 1281-1285. Go to original source... Go to PubMed...
  4. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497. Go to original source... Go to PubMed...
  5. Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-1187.
  6. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: Captopril Prevention Project (CAPP) randomised trial. Lancet 1999; 353: 611-616. Go to original source... Go to PubMed...
  7. Kereiakes DJ, Willerson JT. Metabolic syndrome epidemic. Circulation 2003; 108: 1552-1553. Go to original source... Go to PubMed...
  8. Nadar S, Lim HS, Beevers DG, et al. Lipid lowering in hypertension and heart protection: observation from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study. J Hum Hypertens 2002; 16: 815-817. Go to original source... Go to PubMed...
  9. Nevrlka J, Souček M. Metabolický syndrom a hypertenze. Remedia 2006; 16: 146-151.
  10. Pelikánová T. Metabolický syndrom. Vnitř Lék 2003; 49: 900-906. Go to PubMed...
  11. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of an angiotensin-converting-enzyme inhibotor ramipril on cardiovascular events in high risk patients. New Engl J Med 2000; 324: 145-153. Go to original source... Go to PubMed...
  12. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Finnish Prevention Study Group. Prevention of typ 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350. Go to original source... Go to PubMed...
  13. UK prospective Diabetes Study Group. Tight blood pressurte control and risk of macrovascular and microvascular complication in Type 2 diabetes. UKPDS38. BMJ 1998; 317: 703-713. Go to original source...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.